The Association of the British Pharmaceutical Industry
Medicines are transforming our lives like never before.
We want the UK to be the best place in the world to research, develop and use the medicines and vaccines of the future.
Latest news and blogs
Blog |
International comparisons in medicines spending and the link to competitiveness
Blog |
ABPI Regulatory Science symposium 2025
News |
Decline in commercial clinical trial recruitment selling patients short, says ABPI
News |
UK-US deal is good news for NHS patients and will help to support UK life sciences competitiveness, says ABPI
Best practice guidance: Supporting patient organisations to report industry funding
Transparency is essential when pharmaceutical companies work with patient organisations. This updated guidance is aimed at supporting that transparency.
Guidance for conferences and events in the UK: ABPI Code of Practice requirements
This clarifies the ABPI Code requirements for conferences and events, helps all relevant stakeholders operate in a Code-compliant, professional and ethical manner.
2024 ABPI Code of Practice – new resources
The PMCPA has published new webinars and e-learning to aid understanding of the 2024 ABPI Code of Practice.
Lives Lived Well
From patients and their loved ones to those working within the pharmaceutical industry in the UK, we share a common goal: Lives Lived Well.
Events
ABPI Annual Conference 2026
ABPI’s flagship annual conference will be taking place in Central London on 23 April 2026.
VPAG payment rate for newer medicines will be 14.5% in 2026
The government has announced that the 2026 payment rate for newer medicines under the Voluntary Scheme for Branded Medicines Pricing and Access (VPAG) will be 14.5 per cent, down from a record 22.5 per cent in 2025.
Decline in commercial clinical trial recruitment selling patients short, says ABPI
The low number of patients recruited, together with slow set-up times, is raising costs and lowering the efficiency of industry clinical trials in the UK.
UK-US deal is good news for NHS patients and will help to support UK life sciences competitiveness, says ABPI
Industry hopes the new trade agreement will allow more innovative medicines to reach a greater number of NHS patients and will be a positive step in supporting the UK life sciences industry.
Economic statistics
£17.6bn
direct Gross Value Added (GVA) [1]
£9.3bn
investment in UK R&D in 2024 [2]
£1 in every £6
invested by the private sector in R&D is invested by the pharmaceutical industry [3]